Wells Fargo & Company MN grew its position in shares of Aralez Pharmaceuticals (NASDAQ:ARLZ) by 151.5% in the 4th quarter, HoldingsChannel reports. The fund owned 686,931 shares of the company’s stock after buying an additional 413,801 shares during the period. Wells Fargo & Company MN’s holdings in Aralez Pharmaceuticals were worth $975,000 as of its most recent SEC filing.
ARLZ has been the subject of several recent research reports. HC Wainwright initiated coverage on Aralez Pharmaceuticals in a report on Monday, February 5th. They set a “buy” rating and a $6.00 price objective for the company. Bloom Burton downgraded Aralez Pharmaceuticals from a “buy” rating to an “accumulate” rating in a report on Wednesday, March 14th. Finally, Chardan Capital restated a “buy” rating on shares of Aralez Pharmaceuticals in a report on Tuesday, March 20th.
Shares of NASDAQ:ARLZ opened at $1.35 on Thursday. The company has a market cap of $89.12, a P/E ratio of -1.13 and a beta of 1.59. The company has a debt-to-equity ratio of 18.05, a quick ratio of 0.68 and a current ratio of 0.78. Aralez Pharmaceuticals has a 12-month low of $0.95 and a 12-month high of $2.98.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last announced its earnings results on Tuesday, March 13th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.03). The company had revenue of $28.02 million for the quarter, compared to analysts’ expectations of $25.75 million. Aralez Pharmaceuticals had a negative net margin of 118.18% and a negative return on equity of 170.42%. research analysts predict that Aralez Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial.
Want to see what other hedge funds are holding ARLZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aralez Pharmaceuticals (NASDAQ:ARLZ).
Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.